Prognostic Value of Average Daily Platelet Increase in Childhood B-cell Acute Lymphoblastic Leukemia Patients / 中国实验血液学杂志

OBJECTIVE@#To evaluate the prognosis value of average daily platelet amount increase in children with B-cell acute lymphoblastic leukemia(B-ALL) treated by CCCG-ALL-2015 regimen.@*METHODS@#106 children with primary B-ALL were retrospective analyzed, standardized MRD test protocol was used to detect the MRD level (19 d and 46 d) after chemotherapy. The platelet count was measured by Sysmex XE-2100. Kaplan-Meier survival curve statistics was used to analyze the event free survival(EFS) rate of the children.@*RESULTS@#The trend of negative correlation existed between PPC and TPR (rs=-0.519, P=0.021). The 3-year EFS rate of the patients in Ap>5.4×109/L group was 95.7%, which was significantly higher than those in Ap≤5.4×109/L group(79.5%) (χ2=5.236, P=0.035); multivariate analysis showed that Ap≤5.4×109/L was the independent prognostic factor affecting survival of the patients (RR=3.978; 95%CI: 1.336-11.523, P=0.041). With both MRD and Ap≤5.4×109/L as candidate variables, Ap≤5.4×109/L lost its independent prognostic value (RR=1.225; 95%CI: 0.892-13.696, P=0.089), the correlation between d 19/d 46 MRD levels and Ap>5.4×109/L (χ2=4.318, P=0.038) could explain the phenomenon.@*CONCLUSION@#Ap can reflect the effect of B-ALL chemotherapy and can be used to monitor the curative effect and prognosis of B-ALL children.

Relationship between Immune Differentiation Antigen and Minimal Residual Disease in Childhood B-ALL / 中国实验血液学杂志

<p><b>OBJECTIVE</b>To determine whether immune differentiation antigen is related with clinical features and minimal residual disease (MRD) in childhood B-cell precursor acute lymphoblastic leukemia (B-ALL), who were treated with CCCG-ALL-2015 protocol.</p><p><b>METHODS</b>A retrospective analysis was conducted in 132 B-ALL children, Multiparametric flow cytometry was used to analyze the immunophenotypes. The children were divided into 2 groups by MRD>0.1% on d 19 and / or d 46 after chemotherapy. The Wilcoxon rank-sum test and χ test were used for the comparison between groups, and P<0.05 was considered statistically significant.</p><p><b>RESULTS</b>CD19 (100%), CD22 (99.3%) and cCD79a (97.9%) were specific markers for patients with B-ALL, the CD13 and CD33 were mainly cross myeloid antigen. The significant differences were found between CD45 and CD45 in WBC counts when being firstly diagnosed (Z=6.845, P<0.01), risk stratification (χ=8.260, P<0.05) and prednisone poor responder (χ=18.420, P<0.01). Significant differences were found between CD10 and CD10 in age (Z=6.253, P<0.05), risk stratification (χ=6.699, P<0.05) and MRD (χ=4.951, P<0.05).</p><p><b>CONCLUSION</b>In CCCG-ALL-2015 protocol, the CD10 relates with the early MRD, suggesting a better prognosis, and reducing the adverse effects of CD20 and cross myeloid antigen on prognosis.</p>